Thursday, November 10, 2022 8:09:45 PM
(from a post on yhoo)
Veru (VERU): "See EUA More Likely Than Not " - Oppenheimer Reiterates Stock at Outperform, $36 PT, November 10, 2022 6:30 AM EST
The analyst comments: "At face value, yesterday's advisory committee vote of 5 yes, 8 no to the single voting question of whether sabizabulin's benefits outweigh its risks in those hospitalized with COVID-19 at high risk of ARDS may be taken by some as fait accompli that the FDA will deny VERU's EUA request. Irrespective of their individual votes, all the panel members were favorable on the drug's potential utility and expressed appreciation for the considerably limited amount of efficacy, safety, and mechanistic understanding on sabizabulin, as well as the potential for various aspects of the Phase 3 trial to have biased its outcome. We believe the key distinction between those who voted "yes" vs. "no" was the standard against which this unique case was measured—a standard that may have been unreasonably stringent in the minds of the "no" voters, as the Phase 3 was conducted during a critical/chaotic period of the pandemic in which more ideal trial conditions simply may not have existed.
We believe the most reasonable course of regulatory action will be that which the briefing documents appeared to lay out, that is, for the FDA to authorize sabizabulin for emergency use in the Phase 3 population (WHO 5 and 6, or WHO 4 with comorbidities) and, as a condition of such, stipulate that VERU conduct another randomized double-blind trial in the same population in which patients are fully matched with respect to baseline characteristics and evaluates sabizabulin for superiority to placebo on top of standard of care."
Recent VERU News
- Veru to Present at the GLP-1 Based Therapeutics Summit • GlobeNewswire Inc. • 05/02/2024 12:30:00 PM
- Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024 • GlobeNewswire Inc. • 05/01/2024 12:30:37 PM
- Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss • GlobeNewswire Inc. • 04/30/2024 12:30:00 PM
- Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 • GlobeNewswire Inc. • 04/25/2024 12:30:00 PM
- Veru Announces Date of 2024 Annual Meeting of Shareholders • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- Veru Reschedules Annual Meeting of Shareholders • GlobeNewswire Inc. • 03/22/2024 08:05:00 PM
- Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss • GlobeNewswire Inc. • 03/12/2024 12:00:00 PM
- Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 02/28/2024 12:15:00 AM
- Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss • GlobeNewswire Inc. • 02/20/2024 01:30:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/15/2024 09:49:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:06:36 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:32:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 12:00:37 PM
- Veru Reports Fiscal 2024 First Quarter Financial Highlights • GlobeNewswire Inc. • 02/08/2024 11:30:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:27:50 PM
- Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs • GlobeNewswire Inc. • 02/06/2024 01:30:00 PM
- Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 01/31/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 09:06:01 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2024 02:02:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2024 02:00:32 PM
- Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024 • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss • GlobeNewswire Inc. • 01/08/2024 01:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/26/2023 09:31:07 PM
- Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs • GlobeNewswire Inc. • 12/19/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 02:01:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM